Vanguard reports 19.3M Dexcom shares (5.02%)
Dexcom Inc ownership disclosure: Vanguard Portfolio Management reports beneficial ownership of 19,322,566 shares of Common Stock, representing 5.02% of the class as of 03/31/2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Dexcom Inc ownership disclosure: Vanguard Portfolio Management reports beneficial ownership of 19,322,566 shares of Common Stock, representing 5.02% of the class as of 03/31/2026. The filing shows sole dispositive power over 19,322,566 shares and sole voting power of 102,613 shares. The disclosure states ownership includes securities held by Vanguard funds and certain affiliates and is signed on 04/29/2026 by Ashley Grim.
Insights
Vanguard holds a >5% stake in Dexcom, reported as beneficial ownership via managed accounts.
The filing identifies 19,322,566 shares and a 5.02% ownership stake as of 03/31/2026. This is reported under Schedule 13G, which typically describes passive or investment-manager holdings rather than activist intent.
Watch subsequent filings for any change in voting/dispositive power or conversion to Schedule 13D; timing of any trading activity is not included in the excerpt.
Disclosure clarifies power allocation across Vanguard entities and fund sleeves.
The statement explains that Vanguard Portfolio Management LLC exercises dispositive power across funds and affiliated business divisions. The filing lists sole voting power of 102,613 shares and shared powers as zero, indicating voting control is limited relative to dispositive control.
Investors may track whether any affiliate-level reallocations or subsequent amendments alter reported voting authority; those details are not included here.
Key Figures
Key Terms
Schedule 13G regulatory
Beneficial ownership financial
Dispositive power regulatory
Sole voting power governance
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Vanguard Portfolio Management report in Dexcom (DXCM)?
What filing was used to report this ownership in Dexcom?
Does the filing indicate any change in Vanguard's intentions for the Dexcom stake?
AI-generated analysis. How Rhea-AI works. Not financial advice.